Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Michael E. Williams, MD, of the University of Virginia School of Medicine, Charlottesville, VA, discusses the clinical development of venetoclax, a selective BCL-2 inhibitor, for the treatment of patients with non-Hodgkin lymphoma. Dr Williams focuses on a phase 1 clinical trial that was designed to determine the optimal dosing scheme for the combination of venetoclax and ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma.